REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202

Rhea-AI Summary

REGENXBIO (RGNX) has announced a webcast scheduled for June 5, 2025, at 8:00 a.m. EDT to present new interim functional data from their Phase I/II AFFINITY DUCHENNE trial of RGX-202, a next-generation gene therapy being developed for Duchenne muscular dystrophy. The presentation will feature principal investigator Dr. Aravindhan Veerapandiyan from Arkansas Children's Hospital. The webcast will be accessible through REGENXBIO's website, with a replay available for approximately 30 days after the event.

• Event will feature Aravindhan Veerapandiyan, M.D., principal investigator of the AFFINITY DUCHENNE^® trial

ROCKVILLE, Md., June 2, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a webcast to discuss new interim functional data from the Phase I/II AFFINITY DUCHENNE^® trial of RGX-202, the company's next-generation investigational gene therapy for the treatment of Duchenne muscular dystrophy. The webcast will feature AFFINITY DUCHENNE principal investigator Aravindhan Veerapandiyan, M.D., Arkansas Children's Hospital.

Webcast details
Title: AFFINITY DUCHENNE^® Trial of RGX-202: Phase I/II Interim Functional Data
Date/Time: Thursday, June 5, 2025, at 8:00 a.m. EDT 
Access: The live webcast can be accessed here and in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.

ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit www.REGENXBIO.com.

Contacts:

Dana Cormack
Corporate Communications
dcormack@regenxbio.com 

Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-host-webcast-discussing-interim-functional-data-from-the-phase-iii-affinity-duchenne-trial-of-rgx-202-302470286.html

SOURCE REGENXBIO Inc.

FAQ

When will REGENXBIO (RGNX) present the AFFINITY DUCHENNE trial data?

REGENXBIO will present the interim functional data on Thursday, June 5, 2025, at 8:00 a.m. EDT via webcast.

What is RGX-202 being developed for by REGENXBIO?

RGX-202 is REGENXBIO's next-generation investigational gene therapy being developed for the treatment of Duchenne muscular dystrophy.

Who is the principal investigator of the AFFINITY DUCHENNE trial?

Dr. Aravindhan Veerapandiyan from Arkansas Children's Hospital is the principal investigator of the AFFINITY DUCHENNE trial.

How can investors access REGENXBIO's AFFINITY DUCHENNE trial data presentation?

Investors can access the live webcast through REGENXBIO's website at www.regenxbio.com in the Investors section, with a replay available for approximately 30 days after the presentation.